Clinical Trial Update: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors [Phase 2]

View source ↗

Summary

Ongoing Phase 2 master protocol trial evaluating Genetically Engineered T Cells targeting NY-ESO-1 and LAGE-1a in solid tumors; currently active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Genetically Engineered T Cells targeting NY-ESO-1/LAGE-1a (engineered T cell therapy targeting NY-ESO-1 and LAGE-1a)

Snippet

Sponsor: USWM CT, LLC | Conditions: Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING